Dutch Biotech Creates Blood To Neutralize Southeast Asia Bird Flu Strains
This article was originally published in PharmAsia News
Executive Summary
A Dutch biotechnology firm says it has tested successfully blood it created to neutralize the H5N1 virus based on two major strains found in Vietnam and Indonesia. Crucell said its creation of the specific human monoclonal antibodies could be another way to avoid a feared pandemic of avian influenza. The company said it was able to produce one line of antibodies that neutralized strains found in Hong Kong in 1997, in Vietnam in 2003 and in Indonesia in 2005. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.